Financial Data and Key Metrics Changes - The company reported revenue of $36.7 million for Q3 2022, a 40% increase from Q3 2021 and a 2% sequential growth from Q2 2022 [23][18] - Adjusted EBITDA for Q3 2022 was $7.7 million, up 44% year-over-year, with an adjusted EBITDA margin of 21% [25][19] - For the nine months ended June 30, 2022, revenue increased to $99.8 million, a 36.2% increase compared to the same period in 2021 [26] - Operating expenses as a percentage of revenue increased to 46.7% from 43% in the same period last year, attributed to higher wages and fuel costs [28] Business Line Data and Key Metrics Changes - The company completed 133,704 unique setups in Q3 2022, a 40% increase from the previous year, with respiratory resupply setups increasing by 55% [27] - Recurring revenue now represents approximately 77% of total revenue, indicating a stable revenue base [28][34] Market Data and Key Metrics Changes - The backlog of patients waiting for sleep device setups was approximately 6,000, down from a peak of over 8,000 [14] - The company has expanded its operational footprint to over 90 locations across 19 states, serving over 200,000 active patients [43] Company Strategy and Development Direction - The company aims to expand as a national provider of at-home respiratory services, focusing on organic and inorganic growth through acquisitions and enhancing its healthcare network [6][20] - A national contract with UnitedHealthcare has been secured, significantly expanding patient accessibility and supporting growth initiatives [12] - The company is also pursuing a supply contract with Cardinal Health to enhance cross-selling opportunities and improve buying power [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the improving supply chain dynamics and regulatory environment, which is expected to positively impact margins [14][16] - The company anticipates continued strong demand for its respiratory products, particularly as the supply chain stabilizes [19][20] - Management expects to maintain adjusted EBITDA margins in the range of 20% to 21.5% over the next few quarters [65] Other Important Information - The company has closed four acquisitions since April 2022, adding over 30,000 active patients and contributing approximately $25 million in revenue [36][44] - A new credit facility of up to $80 million has been committed, which will support future growth and acquisitions [39][40] Q&A Session Summary Question: Can you talk about the Cardinal relationship and its expected sales impact? - Management is optimistic about the Cardinal contract and expects it to contribute to organic revenue growth starting in 2023 [62] Question: What operating leverage will the recent acquisitions add? - Management indicated that while there may be a slight initial impact on margins from new acquisitions, they expect to maintain EBITDA margins around 20% to 21.5% [64][65] Question: How quickly can you integrate acquisitions into the resupply program? - Integration typically takes three to six months, and management expects growth in the resupply program as device setups increase [67] Question: Will new de novo locations be in existing or new states? - New locations will primarily be in states where the company already operates to maximize operational leverage [70] Question: How will the CMS inflation adjustments impact margins? - Management believes the inflation adjustments will positively impact margins, with expectations of remaining stable despite potential vendor price increases [80] Question: What are the potential new service verticals? - Management is exploring expansion into supply businesses and technology for remote monitoring [94] Question: How does the company view the economic sensitivity of private pay patients? - Historically, the company has not seen significant impacts on this segment during recessionary periods [90]

Table of Contents Exhibit 99.1 Quipt Home Medical Corp. (Formerly, Protech Home Medical Corp.) Condensed Consolidated Interim Financial Statements 2022 Third Quarter For the three and nine months ended June 30, 2022 and 2021 (UNAUDITED) (Expressed in US Dollars) Table of Contents TABLE OF CONTENTS | Condensed Consolidated Interim Statements of Financial Position | Page 1 | | --- | --- | | Condensed Consolidated Interim Statements of Income (Loss) and Comprehensive Income | | | (Loss) | Page 2 | | Condensed ...

Quipt Home Medical Corp. (NASDAQ:QIPT) Q2 2022 Earnings Conference Call May 17, 2022 10:00 AM ET Company Participants Greg Crawford - Chairman and CEO Hardik Mehta - CFO Conference Call Participants Doug Cooper - Beacon Securities Sepehr Manochehry - Eight Capital Tania Armstrong-Whitworth - Canaccord Genuity Raul Sarugaser - Raymond James Paul Stewardson - IA Capital Markets Justin Keywood - Stifel Stefan Quenneville - Echelon Capital Markets Operator Thank you for standing by. This is the conference opera ...

[Condensed Consolidated Interim Financial Statements](index=3&type=section&id=Condensed%20Consolidated%20Interim%20Financial%20Statements) [Condensed Consolidated Interim Statements of Financial Position](index=3&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Financial%20Position) Total assets grew to $110.5 million, driven by a goodwill increase from acquisitions, while cash decreased significantly **Key Balance Sheet Items (in thousands of US Dollars)** | Account | March 31, 2022 | September 30, 2021 | Change | | :--- | :--- | :--- | :--- | | Cash | $17,394 | $34,612 | ($17,218) | | Accounts receivable, net | $13,710 | $11,938 | $1,772 | | Goodwill | $25,999 | $12,456 | $13,543 | | Total Assets | $110,526 | $108,573 | $1,953 | | Total Liabilities | $44,816 | $49,951 | ($5,135) | | Total Shareholders' Equity | $65,710 | $58,622 | $7,088 | [Condensed Consolidated Interim Statements of Income (Loss) and Comprehensive Income (Loss)](index=4&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Income%20(Loss)%20and%20Comprehensive%20Income%20(Loss)) The company achieved a net income of $5.0 million in Q2 2022, a turnaround driven by revenue growth and a government grant **Income Statement Highlights (in thousands of US Dollars)** | Metric | Q2 2022 (3 months) | Q2 2021 (3 months) | YoY Change | Six Months 2022 | Six Months 2021 | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Total Revenues | $33,553 | $24,240 | +38.4% | $63,077 | $46,995 | +34.2% | | Operating Income | $4,444 | $1,418 | +213.4% | $3,262 | $2,847 | +14.6% | | Other Income (Gov't Grant) | $4,254 | $0 | N/A | $4,254 | $0 | N/A | | Net Income (Loss) | $5,036 | ($12,490) | Turnaround | $2,905 | ($11,125) | Turnaround | | Basic EPS | $0.15 | ($0.43) | Turnaround | $0.09 | ($0.39) | Turnaround | [Condensed Consolidated Interim Statements of Changes in Shareholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Changes%20in%20Shareholders'%20Equity) Shareholders' equity grew to $65.7 million, primarily driven by net income and stock-based compensation **Reconciliation of Shareholders' Equity (in thousands of US Dollars)** | Description | Amount | | :--- | :--- | | **Balance at September 30, 2021** | **$58,622** | | Net income | $2,905 | | Conversion of debentures | $887 | | Stock options exercised | $25 | | Stock-based compensation | $3,271 | | **Balance at March 31, 2022** | **$65,710** | [Condensed Consolidated Interim Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Cash%20Flows) Operating cash flow doubled to $12.2 million, but cash decreased by $17.3 million due to acquisition and financing activities **Cash Flow Summary (Six months ended March 31, in thousands of US Dollars)** | Activity | 2022 | 2021 | | :--- | :--- | :--- | | Net cash flow provided by operating activities | $12,193 | $6,624 | | Net cash flow used in investing activities | ($19,941) | ($8,695) | | Net cash flow used in financing activities | ($9,553) | ($962) | | **Net decrease in cash** | **($17,301)** | **($3,033)** | | Cash, beginning of period | $34,612 | $29,227 | | **Cash, end of period** | **$17,394** | **$27,158** | - Cash paid for acquisitions was a major use of cash, increasing to **$16.5 million** in the first six months of fiscal 2022 from $7.7 million in the prior-year period[10](index=10&type=chunk) [Notes to the Condensed Consolidated Interim Financial Statements](index=8&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Interim%20Financial%20Statements) [Note 1: Nature of Operations](index=9&type=section&id=1.%20Nature%20of%20operations) The company provides medical respiratory equipment, pursues an acquisition-based growth strategy, and faces COVID-19 related risks - The company provides durable medical respiratory equipment and services and is actively pursuing an **acquisition-based growth strategy**[11](index=11&type=chunk) - The company changed its name to Quipt Home Medical Corp on May 13, 2021, and began trading on **NASDAQ** under the symbol **QIPT** on May 27, 2021[12](index=12&type=chunk)[13](index=13&type=chunk) - The company identifies **significant risks from the COVID-19 pandemic**, including potential disruptions to supply chains, changes in patient demand, and general economic deterioration[15](index=15&type=chunk)[16](index=16&type=chunk)[19](index=19&type=chunk) [Note 2: Summary of Significant Accounting Policies](index=12&type=section&id=2.%20Summary%20of%20significant%20accounting%20policies) Key accounting policies include critical estimates for revenue recognition, accounts receivable valuation, and business combinations - **Revenue recognition is a critical estimate**, as amounts billed to third-party insurers are variable and reduced by an estimated allowance based on historical collection data[26](index=26&type=chunk)[27](index=27&type=chunk) - The **valuation of accounts receivable** and the associated reserve for expected credit losses involve significant judgment, incorporating historical data and forward-looking factors like unemployment and inflation[36](index=36&type=chunk)[37](index=37&type=chunk) - **Accounting for business combinations requires management judgment** to determine if a transaction is a business or asset acquisition and to estimate the fair value of acquired assets and liabilities[48](index=48&type=chunk) [Note 3: Acquisition of Businesses](index=23&type=section&id=3.%20Acquisition%20of%20businesses%20and%20purchase%20accounting) The company completed four acquisitions for $16.5 million in cash, adding $13.5 million to goodwill **Summary of Acquisitions (Six Months Ended March 31, 2022)** | Acquired Company | Date | Purchase Price (in thousands) | Goodwill (in thousands) | | :--- | :--- | :--- | :--- | | Thrift Home Care, Inc | Oct 1, 2021 | $2,171 | $1,373 | | Heckman Healthcare | Nov 1, 2021 | $2,434 | $1,351 | | Southeastern Biomedical | Nov 9, 2021 | $697 | $487 | | At Home Health Equipment | Jan 1, 2022 | $13,265 | $10,332 | - The balance of **purchase price payable for acquisitions increased** from $2.5 million at September 30, 2021, to **$3.4 million** at March 31, 2022, after additions from new acquisitions and payments on prior ones[75](index=75&type=chunk) [Note 4: Accounts Receivable](index=30&type=section&id=4.%20Accounts%20Receivable) Net accounts receivable increased to $13.7 million, with a corresponding rise in the reserve for credit losses **Accounts Receivable Aging (in thousands of US Dollars)** | Aging | Gross Receivable (Mar 31, 2022) | Net Receivable (Mar 31, 2022) | Gross Receivable (Sep 30, 2021) | Net Receivable (Sep 30, 2021) | | :--- | :--- | :--- | :--- | :--- | | 0 – 90 days | $15,144 | $12,245 | $11,279 | $9,861 | | 91 – 180 days | $2,591 | $1,163 | $2,027 | $1,296 | | Over 180 days | $1,999 | $302 | $2,107 | $781 | | **Total** | **$19,734** | **$13,710** | **$15,413** | **$11,938** | [Note 7: Goodwill and Intangible Assets](index=32&type=section&id=7.%20Goodwill%20and%20Intangible%20Assets) Goodwill more than doubled to $26.0 million due to a $13.5 million increase from business acquisitions **Change in Goodwill and Intangibles (in thousands of US Dollars)** | Account | March 31, 2022 | September 30, 2021 | Change | | :--- | :--- | :--- | :--- | | Goodwill | $25,999 | $12,456 | +$13,543 | | Intangibles with finite lives, net | $13,959 | $14,874 | -$915 | | **Total** | **$39,958** | **$27,330** | **+$12,628** | [Note 8: Government Grant](index=34&type=section&id=8.%20Government%20Grant) The company recognized $4.25 million in other income from the forgiveness of a Payroll Protection Program (PPP) loan - On March 23, 2022, the company's **$4,254,000 Payroll Protection Plan (PPP) loan was forgiven**, and this amount was recognized as other income[85](index=85&type=chunk) [Note 11: Long-Term Debt](index=36&type=section&id=11.%20Long-term%20Debt) Long-term debt includes convertible debentures and loans, with an undrawn $20 million credit facility providing liquidity - The company has **C$10.1 million ($8.1 million) in face value of convertible debentures** outstanding, resulting in a fair value **gain of $1.1 million** for the six months ended March 31, 2022[94](index=94&type=chunk)[96](index=96&type=chunk) - The company has a **$20 million asset-based revolving credit facility** that matures in September 2024, with **no borrowings** as of March 31, 2022[107](index=107&type=chunk) [Note 12: Share Capital](index=41&type=section&id=12.%20Share%20capital) Stock-based compensation expense increased substantially to $3.3 million, driven by stock options and new RSU grants **Stock-Based Compensation Expense (in thousands of US Dollars)** | Period | 2022 | 2021 | Change | | :--- | :--- | :--- | :--- | | Three Months Ended Mar 31 | $1,161 | $12 | +$1,149 | | Six Months Ended Mar 31 | $3,271 | $27 | +$3,244 | - The company granted **81,340 restricted stock units (RSUs)** to officers on February 1, 2022, and had a total of **895,000 RSUs outstanding** as of March 31, 2022[123](index=123&type=chunk)[125](index=125&type=chunk) [Note 14: Operating Expenses](index=47&type=section&id=14.%20Operating%20expenses) Operating expenses increased 45% to $35.2 million, driven by higher payroll, bad debt, and professional fees **Operating Expense Breakdown (Six months ended March 31, in thousands of US Dollars)** | Expense Category | 2022 | 2021 | Change | | :--- | :--- | :--- | :--- | | Payroll and employee benefits | $18,583 | $13,435 | +$5,148 | | Bad debt expense | $5,579 | $4,289 | +$1,290 | | Professional fees | $1,970 | $1,000 | +$970 | | Billing | $2,846 | $1,609 | +$1,237 | | **Total operating expenses** | **$35,249** | **$24,263** | **+$10,986** | [Note 17: Subsequent Event](index=49&type=section&id=17.%20Subsequent%20event) The company acquired Good Night Medical for $6.1 million on April 1, 2022, after the reporting period - On April 1, 2022, the company acquired **Good Night Medical, LLC** for a purchase price of **$6.1 million**[137](index=137&type=chunk) - The pro forma six-month revenues and net income for Good Night are estimated to be **$5.3 million** and **$280,000**, respectively[138](index=138&type=chunk)

Exhibit 99.1 Notice to Reader The unaudited condensed consolidated interim financial statements for the three months ended December 31, 2021 and 2020 are being refiled now that they have been reviewed by the Company's auditor. Accordingly, apart from the removal of the Notice of No Auditor Review, no other changes were made to the information initially filed, Quipt Home Medical Corp. (Formerly, Protech Home Medical Corp.) Amended Condensed Consolidated Interim Financial Statements 2022 First Quarter For the ...

Quipt Home Medical Corp. (NASDAQ:QIPT) Q4 2021 Earnings Conference Call February 1, 2022 10:00 AM ET Company Participants Greg Crawford - Chairman & Chief Executive Officer Hardik Mehta - Chief Financial Officer Conference Call Participants Doug Cooper - Beacon Securities Sepehr Manochehry - Eight Capital Paul Stewardson - IA Capital Markets Justin Keywood - Stifel GMP Michael Freeman - Raymond James Bill Sutherland - The Benchmark Company Operator Thank you for standing by. This is the conference operator. ...

Quipt Home Medical Corp. (NASDAQ:QIPT) Q3 2021 Earnings Conference Call August 24, 2021 10:00 AM ET Company Participants Greg Crawford - Chairman and Chief Executive Officer Hardik Mehta - Chief Financial Officer Conference Call Participants Doug Cooper - Beacon Securities Doug Loe - Leede Jones Gable Sepehr Manochehry - Eight Capital Justin Keywood - Stifel Bill Sutherland - Benchmark Company Rahul Sarugaser - Raymond James Chelsea Stellick - iA Capital Markets Dick Ryan - Colliers Securities Operator Than ...

TSXV:QIPT NASDAQ:QIPT QUIPT HOME MEDICAL CORPORATE PRESENTATION JUNE 2021 "exceeding expectations, enriching lives" SM Table of Contents 2 q Forward-Looking Statements q Company & Industry Overview q Strategic Growth Initiatives q Acquisitions Summary q Financial Information q Management Team Forward Looking Statements QIPT This presentation (the "Presentation") about Quipt Home Medical Corp. (the "Company") is dated as of June 1, 2021. It isinformation in a summary form and does not purport to be complete. ...

Protech Home Medical Corp. (PTQQF) Q1 2021 Earnings Conference Call March 2, 2021 10:00 AM ET Company Participants Greg Crawford - Chairman and CEO Hardik Mehta - CFO Conference Call Participants Rahul Sarugaser - Raymond James Doug Cooper - Beacon Securities Justin Keywood - Stiefel, GMP Paul Stewardson - Industrial Alliance Tania Gonsalves - Canaccord Operator Thank you for standing by. This is the conference operator. Welcome to the First Quarter Fiscal 2021 Financial Results Conference Call and webcast ...

Protech Home Medical Corp. (PTQQF) Q4 2020 Earnings Conference Call February 2, 2021 4:00 PM ET Company Participants Greg Crawford - Chairman and Chief Executive Officer Hardik Mehta - Chief Financial Officer Conference Call Participants Doug Cooper - Beacon Securities Stefan Quenneville - Echelon Capital Markets Michael Freeman - Raymond James Dick Ryan - Clear Securities Operator Thank you for standing by. This is the conference operator. Welcome to the Fourth Quarter and Audited Full Year Fiscal 2020 Ear ...